Well Referenced

Tag: prostate cancer treatment

Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

This 2021 commentary by Hadaschik and Herrmann discusses the findings of the VISION trial, which evaluated the efficacy of Lutetium-177-PSMA-617 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated that Lu-PSMA-617, when added to standard care, significantly improved both imaging-based progression-free survival (8.7 vs. 3.4 months)

Read More »
June 26, 2025 No Comments

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

This 2017 editorial discusses bipolar androgen therapy (BAT) as a novel treatment strategy for castration-resistant prostate cancer (CRPC). BAT involves alternating testosterone levels between supraphysiologic and near-castrate concentrations, aiming to exploit the paradoxical effects of androgen exposure on tumor cells. Initial studies have shown that BAT is safe and can

Read More »
June 26, 2025 No Comments